Oluyemi Okupe Sells 11,581 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the business’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.22, for a total value of $697,407.82. Following the completion of the sale, the chief financial officer now directly owns 113,816 shares of the company’s stock, valued at approximately $6,853,999.52. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, April 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.50, for a total value of $330,058.50.
• On Wednesday, April 2nd, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.26, for a total value of $338,860.06.

Hims & Hers Health Trading Down 1.8%

Shares of NYSE HIMS opened at $61.21 on Wednesday. The stock has a 50 day simple moving average of $36.60 and a 200-day simple moving average of $34.38. The company has a market cap of $13.70 billion, a PE ratio of 139.12 and a beta of 1.84. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue was up 110.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 earnings per share. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of several research analyst reports. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Morgan Stanley lowered their target price on Hims & Hers Health from $60.00 to $40.00 and set an “equal weight” rating for the company in a report on Tuesday, April 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $61.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 6th. Bank of America upped their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a report on Tuesday, April 29th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $37.67.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Intech Investment Management LLC lifted its position in Hims & Hers Health by 74.5% in the first quarter. Intech Investment Management LLC now owns 143,287 shares of the company’s stock worth $4,234,000 after purchasing an additional 61,195 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares during the period. Arete Wealth Advisors LLC acquired a new stake in Hims & Hers Health in the first quarter worth approximately $300,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Hims & Hers Health by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 211,480 shares of the company’s stock worth $6,249,000 after purchasing an additional 6,876 shares during the period. Finally, Bosun Asset Management LLC acquired a new stake in Hims & Hers Health in the first quarter worth approximately $272,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.